Singapore’s Phaidros Healthcare and Taiwan based Vigorous Pharma have entered into a commercial agreement for the market launch of a number of fertility brands in Taiwan.
The deal initially comprises 3 products out of Phaidros’s reproductive health portfolio, namely Fertiprep, Fertigel and Atrophyl Gel, aimed at alleviating male and female fertility challenges.
After South Korea, Taiwan is the second East Asian market in which Phaidros has been securing a commercial partnership.
“Vigorous’s focus on the fertility segment presents an excellent fit for our offerings and we are glad to be able to make part of our BonaVidea product range available in Taiwan”, says Marc Wiethuechter, Managing Director of Phaidros.
Phaidros is a young healthcare company focusing on the development and commercialization of strongly differentiated non-prescription drugs and medical devices, especially in the therapeutic areas reproductive medicine and intimate care.
The company has offices in Singapore and Berlin.
Vigorous Pharma is a Taiwanese healthcare company focussing of the therapeutic area of reproductive health. Vigorous is based in Taipei.